{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:40:16Z","timestamp":1781620816399,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T00:00:00Z","timestamp":1588809600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T00:00:00Z","timestamp":1588809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Eleventh Five-Year Support Project of the Ministry of Science and Technology from Ministry of Public Health of China","award":["2010ZX09101-107"],"award-info":[{"award-number":["2010ZX09101-107"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Poverty"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>China is the second highest pulmonary tuberculosis (PTB) burden country worldwide. However, retreatment of PTB has often developed resistance to at least one of the four first-line anti-TB drugs. The cure rate (approximately 50.0\u201373.3%) and management of retreatment of PTB in China needs to be improved. Qinbudan decoction has been widely used to treat PTB in China since the 1960s. Previously clinical studies have shown that the Qinbudan tablet (QBDT) promoted sputum-culture negative conversion and lesion absorption. However, powerful evidence from a randomized controlled clinical trial is lacking. Therefore, the aim of this study was to compare the efficacy and safety of QBDT as an adjunct therapy for retreatment of PTB.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a multicenter, randomized, double-blind, placebo-controlled clinical trial in China. People diagnosed with PTB were enrolled who received previous anti-TB treatment from April 2011 to March 2013. The treatment group received an anti-TB regimen and QBDT, and the control group was administered an anti-TB regimen plus placebo. Anti-TB treatment options included isoniazid, rifampicin, pyrazinamide, ethambutol, streptomycin for 2 months (2HRZES), followed by isoniazid, rifampicin, ethambutol for 6 months (6HRE), daily for 8 months. Primary outcome was sputum-culture conversion using the MGIT 960 liquid medium method. Secondary outcomes included lung lesion absorption and cavity closure. Adverse events and reactions were observed after treatment. A structured questionnaire was used to record demographic information and clinical symptoms of all subjects. Data analysis was performed by SPSS 25.0 software in the full analysis set (FAS) population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One hundred eighty-one cases of retreatment PTB were randomly divided into two groups: the placebo group (88 cases) and the QBDT group (93 cases). A total of 166 patients completed the trial and 15 patients lost to follow-up. The culture conversion rate of the QBDT group and placebo group did not show a noticeable improvement by using the covariate sites to correct the rate differences (79.6% vs 69.3%; rate difference\u2009=\u20090.10, 95% confidence interval (<jats:italic>CI)<\/jats:italic>: -\u20090.02\u20130.23; <jats:italic>F<\/jats:italic>\u2009=\u20092.48, <jats:italic>P<\/jats:italic>\u2009=\u20090.12) after treatment. A significant 16.6% increase in lesion absorption was observed in the QBDT group when compared with the placebo group (67.7% vs 51.1%; rate difference\u2009=\u20090.17, 95% <jats:italic>CI<\/jats:italic>: 0.02\u20130.31; <jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20095.56, <jats:italic>P<\/jats:italic>\u2009=\u20090.02). The intervention and placebo group did not differ in terms of cavity closure (25.5% vs 21.1%; rate difference\u2009=\u20090.04, 95% <jats:italic>CI<\/jats:italic>: -\u20090.21\u20130.12; <jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20090.27, <jats:italic>P<\/jats:italic>\u2009=\u20090.60). Two patients who received chemotherapy and combined QBDT reported pruritus\/nausea and vomiting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>No significant improvement in culture conversion was observed for retreatment PTB with traditional Chinese medicine plus standard anti-TB regimen. However, QBDT as an adjunct therapy significantly promoted lesion absorption, thereby reducing lung injury due to <jats:italic>Mycobacterium tuberculosis<\/jats:italic> infection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>This trial is registered at ClinicalTrials.gov, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02313610\">NCT02313610<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40249-020-00660-z","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T08:05:25Z","timestamp":1588838725000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Improvement cues of lesion absorption using the adjuvant therapy of traditional Chinese medicine Qinbudan tablet for retreatment pulmonary tuberculosis with standard anti-tuberculosis regimen"],"prefix":"10.1186","volume":"9","author":[{"given":"Shao-Yan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-You","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding-Zhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Rong","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He-Ping","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Hui","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun-Yi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Feng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-Long","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Juan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Yong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Hui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,7]]},"reference":[{"key":"660_CR1","unstructured":"World Health Organization. Global tuberculosis report 2019. Geneva: World Health Organization. https:\/\/www.who.int\/tb\/publications\/global_report\/en\/. Accessed 17 Oct 2019."},{"issue":"5","key":"660_CR2","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1183\/09031936.05.00103004","volume":"25","author":"JA Caminero","year":"2005","unstructured":"Caminero JA. Management of multidrug-resistant tuberculosis and patients in retreatment. Eur Respir J. 2005;25(5):928\u201336.","journal-title":"Eur Respir J"},{"issue":"2","key":"660_CR3","doi-asserted-by":"publisher","first-page":"e0148041","DOI":"10.1371\/journal.pone.0148041","volume":"11","author":"Q Duan","year":"2016","unstructured":"Duan Q, Chen Z, Chen C, Zhang Z, Lu Z, Yang Y, et al. The prevalence of drug-resistant tuberculosis in mainland China: an updated systematic review and meta-analysis. PLoS One. 2016;11(2):e0148041.","journal-title":"PLoS One"},{"issue":"23","key":"660_CR4","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1056\/NEJMoa1108789","volume":"366","author":"Y Zhao","year":"2012","unstructured":"Zhao Y, Xu S, Wang L, Chin DP, Wang S, Jiang G, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med. 2012;366(23):2161\u201370.","journal-title":"N Engl J Med"},{"issue":"1","key":"660_CR5","first-page":"25","volume":"41","author":"YH Liu","year":"2018","unstructured":"Liu YH, Gao WW, Li L, Du J, Ma Y, Shu W, et al. The effectiveness of individualized treatment regimen on smear-positive retreatment pulmonary tuberculosis with mono- and poly-drug resistance. Zhonghua Jie He He Hu Xi Za Zhi. 2018;41(1):25\u201331 (in Chinese).","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"issue":"5","key":"660_CR6","first-page":"341","volume":"39","author":"MY Yang","year":"2013","unstructured":"Yang MY, Li CX, Xiang XD. Analyzing of treatment effect in recurrence of pulmonary tuberculosis for drug-resistant. J Modern Clin Med. 2013;39(5):341\u20132 (in Chinese).","journal-title":"J Modern Clin Med"},{"issue":"5","key":"660_CR7","doi-asserted-by":"publisher","first-page":"e10799","DOI":"10.1371\/journal.pone.0010799","volume":"5","author":"GX He","year":"2010","unstructured":"He GX, Xie YG, Wang LX, Borgdorff MW, van der Werf MJ, Fan JH, et al. Follow-up of patients with multidrug resistant tuberculosis four years after standardized first-line drug treatment. PLoS One. 2010;5(5):e10799.","journal-title":"PLoS One"},{"issue":"6","key":"660_CR8","doi-asserted-by":"publisher","first-page":"e65037","DOI":"10.1371\/journal.pone.0065037","volume":"8","author":"X Lv","year":"2013","unstructured":"Lv X, Tang S, Xia Y, et al. Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: a prospective study. PLoS One. 2013;8(6):e65037.","journal-title":"PLoS One"},{"issue":"7","key":"660_CR9","first-page":"1433","volume":"39","author":"SS Wang","year":"2012","unstructured":"Wang SS, Zhou J, Zhang YF, Wang L, Feng X, Li HL, et al. Research progress of Chinese medicine treatment of pulmonary tuberculosis. Liaoning J Tradit Chin Med. 2012;39(7):1433\u20135 (in Chinese).","journal-title":"Liaoning J Tradit Chin Med"},{"issue":"07","key":"660_CR10","first-page":"104","volume":"27","author":"LJ Wang","year":"2013","unstructured":"Wang LJ. Random parallel control study of Baihe Gujin decoction treated recurrent pulmonary tuberculosis. J Prac Tradit Chin Int Med. 2013;27(07):104\u20135 (in Chinese).","journal-title":"J Prac Tradit Chin Int Med"},{"issue":"9","key":"660_CR11","first-page":"801","volume":"51","author":"HX Deng","year":"2010","unstructured":"Deng HX, Liu YK, Jiang Z. Effect of Laokang decoction on the recurrent pulmonary tuberculosis in the TCM syndrome of Yin deficiency with toxic stasis-clinical observation on 48 patients. J Tradit Chin Med. 2010;51(9):801\u20133 (in Chinese).","journal-title":"J Tradit Chin Med"},{"issue":"6","key":"660_CR12","first-page":"385","volume":"28","author":"ZJ Chen","year":"2006","unstructured":"Chen ZJ, Huang YF, Zheng SF, Wu SY, Yang Y, Fu H. Observation of supplementary treatment effect of Yifeizhike capsule in treating re-treatment pulmonary tuberculosis patients. Chin J Antitubercul. 2006;28(6):385\u20137 (in Chinese).","journal-title":"Chin J Antitubercul"},{"key":"660_CR13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/1471-2458-8-365","volume":"8","author":"Q Liu","year":"2008","unstructured":"Liu Q, Garner P, Wang Y, Huang B, Smith H. Drugs and herbs given to prevent hepatotoxicity of tuberculosis therapy: systematic review of ingredients and evaluation studies. BMC Public Health. 2008;8:365.","journal-title":"BMC Public Health"},{"key":"660_CR14","first-page":"002","volume":"9","author":"CR Shao","year":"1965","unstructured":"Shao CR, Tu GY, Tu BY, Hu WP, Zhu ZW, Tao MY. Chinese medicine treatment efficacy against cavitary tuberculosis of drug-resistance pulmonary tuberculosis. Shanghai J Tradit Chin Med. 1965;9:002 (in Chinese).","journal-title":"Shanghai J Tradit Chin Med"},{"key":"660_CR15","first-page":"520","volume":"6","author":"HH Xue","year":"2010","unstructured":"Xue HH, Zhang HY, Lu ZX, Geng PH. The experience of pulmonary tuberculosis treatment by Qinbudan tablets from Shao Changrong. J Shangdong Univ Tradit Chin Med. 2010;6:520\u20131 (in Chinese).","journal-title":"J Shangdong Univ Tradit Chin Med"},{"key":"660_CR16","first-page":"013","volume":"21","author":"CH Lu","year":"2014","unstructured":"Lu CH, Lu JY, Geng PH, Guo XY, Xue HH, Lu ZX, et al. Clinical observation on compound Qinbu pill for 35 multi-drug resistant tuberculosis patients with qi-Yin deficiency syndrome. J Tradit Chin Med. 2014;21:013 (in Chinese).","journal-title":"J Tradit Chin Med"},{"issue":"1","key":"660_CR17","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1186\/1472-6882-14-400","volume":"14","author":"Y Zheng","year":"2014","unstructured":"Zheng Y, Jiang X, Gao F, Song J, Sun J, Wang L, et al. Identification of plant-derived natural products as potential inhibitors of the Mycobacterium tuberculosis proteasome. BMC Complement Altern Med. 2014;14(1):400.","journal-title":"BMC Complement Altern Med"},{"key":"660_CR18","first-page":"6","volume":"26","author":"JX Liu","year":"2011","unstructured":"Liu JX, Li MY, Chen H. Experimental study of 7 kinds of Chinese medicine against multidrug-resistant Mycobacterium tuberculosis. Chin Community Doctors: Med. 2011;26:6 (in Chinese).","journal-title":"Chin Community Doctors: Med"},{"key":"660_CR19","unstructured":"Zhao Y. Detection of drug-resistance genes and biological changes effected by Chinese medicine herb in Mycobacterium tuberculosis. China: Quartermaster University of PLA; 2003. (in Chinese)."},{"issue":"12","key":"660_CR20","first-page":"1089","volume":"21","author":"XY Ji","year":"2000","unstructured":"Ji XY, Tan BK, Zhu YZ. Salvia miltiorrhiza and ischemic diseases. Acta Pharmacol Sin. 2000;21(12):1089\u201394.","journal-title":"Acta Pharmacol Sin"},{"key":"660_CR21","first-page":"018","volume":"8","author":"L Yin","year":"2012","unstructured":"Yin L, Zhu M, Zhou M. Clinical observation on Buqin tablet combined with western medicine for 17 cases of multidrug-resistant tuberculosis. J Tradit Chin Med. 2012;8:018 (in Chinese).","journal-title":"J Tradit Chin Med"},{"key":"660_CR22","first-page":"021","volume":"22","author":"P Wang","year":"2011","unstructured":"Wang P, Zhou M, Li F. Analysis on the attenuation effect of traditional Chinese medicine on anti-tuberculosis drugs. J Tradit Chin Med. 2011;22:021 (in Chinese).","journal-title":"J Tradit Chin Med"},{"issue":"8","key":"660_CR23","first-page":"2028","volume":"21","author":"XY Guo","year":"2010","unstructured":"Guo XY, Zhang HY, Lu ZH, Geng PH. Research progress of treatment of drug-resistant pulmonary tuberculosis by Chinese medcine. Lishizhen Med Materia Med Res. 2010;21(8):2028 (in Chinese).","journal-title":"Lishizhen Med Materia Med Res"},{"key":"660_CR24","first-page":"024","volume":"9","author":"LX Wang","year":"2011","unstructured":"Wang LX, Wu YY, Wang Y. Effect of Qibudan on expression of TLR2 in tuberculosis infection. Chin Pharm Bull. 2011;9:024.","journal-title":"Chin Pharm Bull"},{"key":"660_CR25","unstructured":"Chow S, Shao J, Wang H. Sample size calculations in clinical research. 2nd ed. Oxford, UK: Chapman & Hall\/CRC Biostatistics Series; 2008. p. 89."},{"key":"660_CR26","volume-title":"Pharmacopoeia of the People\u2019s Republic of China","author":"Chinese Pharmacopoeia Commission","year":"2005","unstructured":"Chinese Pharmacopoeia Commission. Pharmacopoeia of the People\u2019s Republic of China. Beijing: People\u2019s Medical Publishing House; 2005. in Chinese."},{"key":"660_CR27","volume-title":"Guidelines for the programmatic management of pulmonary tuberculosis: update 2008","author":"World Health Organization","year":"2008","unstructured":"World Health Organization. Guidelines for the programmatic management of pulmonary tuberculosis: update 2008. China: Ministry of Public Health of China; 2008. in Chinese."},{"key":"660_CR28","first-page":"21","volume-title":"Tuberculosis Health Education","author":"Guideline for TB drug resistance surveillance","year":"2003","unstructured":"Guideline for TB drug resistance surveillance. Tuberculosis Health Education; 2003. p. 21\u201333. (2), (in Chinese)."},{"key":"660_CR29","first-page":"64","volume-title":"Clinical treatment guidelines (TB Volume)","author":"Chinese Medical Association","year":"2005","unstructured":"Chinese Medical Association. Clinical treatment guidelines (TB Volume). Beijing: People\u2019s Medical Publishing House; 2005. p. 64\u201386. in Chinese."},{"key":"660_CR30","volume-title":"Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008","author":"World Health Organization","year":"2008","unstructured":"World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. Geneva: World Health Organization; 2008."},{"issue":"5","key":"660_CR31","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/resp.12762","volume":"21","author":"X Bai","year":"2016","unstructured":"Bai X, Oberley-Deegan RE, Bai A, Ovrutsky AR, Kinney WH, Weaver M, et al. Curcumin enhances human macrophage control of Mycobacterium tuberculosis infection. Respirology. 2016;21(5):951\u20137.","journal-title":"Respirology."}],"container-title":["Infectious Diseases of Poverty"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-020-00660-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40249-020-00660-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-020-00660-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T23:51:54Z","timestamp":1620345114000},"score":1,"resource":{"primary":{"URL":"https:\/\/idpjournal.biomedcentral.com\/articles\/10.1186\/s40249-020-00660-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,7]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["660"],"URL":"https:\/\/doi.org\/10.1186\/s40249-020-00660-z","relation":{},"ISSN":["2049-9957"],"issn-type":[{"value":"2049-9957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,7]]},"assertion":[{"value":"23 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Prior to trial initiation, investigators obtained approval of ethical documents from the Institutional Review Board of Longhua Hospital, Shanghai University of TCM in China on December 16th 2010 (No: 2010LCSY014) and drug clinical trial for QBDT from China Food and Drug Administration (No: 2009\u2009L00473). This trial is registered at ClinicalTrials.gov(NCT02313610).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}